Mabpharm Limited (HK:2181) has released an update.
Mabpharm Limited has announced structural changes to its leadership team, effective July 10, 2024, including the appointment of Mr. Cen Jialin as a non-executive Director, Dr. Tao Qian as an independent non-executive Director, and the re-designation and promotion of Dr. Qian Weizhu to executive Director and vice president. Additionally, Mr. Li Yunfeng transitions from the CFO to a vice president role. These appointments and re-designations reflect the company’s strategic adjustments in its executive team.
For further insights into HK:2181 stock, check out TipRanks’ Stock Analysis page.
